ASLAN Pharmaceuticals (ASLN) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ASLN shares.
View ASLN analyst ratings or view top-rated stocks.

3 analysts have issued 1 year target prices for ASLAN Pharmaceuticals' stock. Their ASLN share price forecasts range from $15.00 to $17.00. On average, they predict the company's stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 679.4% from the stock's current price.
View analysts price targets for ASLN or view top-rated stocks among Wall Street analysts.

ASLAN Pharmaceuticals' stock was trading at $1.80 at the beginning of 2023. Since then, ASLN stock has increased by 11.7% and is now trading at $2.01.
View the best growth stocks for 2023 here.

ASLAN Pharmaceuticals saw a drop in short interest in August. As of August 31st, there was short interest totaling 244,500 shares, a drop of 20.8% from the August 15th total of 308,900 shares. Based on an average trading volume of 124,400 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.8% of the shares of the company are sold short.
View ASLAN Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023.
View our ASLN earnings forecast.

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) announced its quarterly earnings results on Friday, August, 11th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.80) by $0.69. The firm earned $12 million during the quarter.

Shares of ASLAN Pharmaceuticals reverse split on Monday, March 13th 2023. The 1-5 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Onconova Therapeutics (ONTX), Aldeyra Therapeutics (ALDX), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

(ASLN) raised $60 million in an initial public offering (IPO) on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

ASLAN Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASLN."

ASLAN Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (6.42%), Schonfeld Strategic Advisors LLC (0.33%), Renaissance Technologies LLC (0.18%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%).

Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ASLN stock can currently be purchased for approximately $2.01.

ASLAN Pharmaceuticals (NASDAQ:ASLN) has a market capitalization of $32.86 million. The company earns $-51,380,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis.

ASLAN Pharmaceuticals' mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The official website for the company is www.aslanpharma.com. The company can be reached via phone at 65-6817-9598, via email at investor@aslanpharma.com, or via fax at 65-6225-2419.